Compare DOCN & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DOCN | ABVX |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 11.9B |
| IPO Year | 2021 | 2022 |
| Metric | DOCN | ABVX |
|---|---|---|
| Price | $141.91 | $94.90 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 13 |
| Target Price | $85.46 | ★ $131.31 |
| AVG Volume (30 Days) | ★ 2.3M | 1.2M |
| Earning Date | 05-05-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 183.15 | N/A |
| EPS | ★ 0.45 | N/A |
| Revenue | ★ $901,427,000.00 | N/A |
| Revenue This Year | $23.80 | $52.14 |
| Revenue Next Year | $30.11 | $4,132.27 |
| P/E Ratio | $313.80 | ★ N/A |
| Revenue Growth | ★ 15.48 | N/A |
| 52 Week Low | $33.69 | $69.81 |
| 52 Week High | $187.50 | $148.83 |
| Indicator | DOCN | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 58.34 | N/A |
| Support Level | $106.83 | N/A |
| Resistance Level | $140.15 | N/A |
| Average True Range (ATR) | 9.38 | 0.00 |
| MACD | 2.68 | 0.00 |
| Stochastic Oscillator | 69.79 | 0.00 |
DigitalOcean Holdings Inc is a cloud computing platform offering on-demand infrastructure and platform tools for developers, start-ups, and small and medium-sized businesses. The customers use the platform for a wide range of cases, such as web and mobile applications, website hosting, e-commerce, media and gaming, personal web projects, and managed services, among many others. Geographically, the company generates maximum revenue from North America and also has a presence in Europe, Asia, and the Rest of the world.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.